Neurogene's 15min chart shows a KDJ Golden Cross with a bullish Marubozu.

Neurogene's 15-minute chart has exhibited a significant bullish trend, as evidenced by the KDJ Golden Cross and Bullish Marubozu at 09/09/2025 12:15. This indicates a shift in momentum towards the upside, suggesting that the stock price has potential to further increase. With buyers maintaining control of the market, it is likely that the bullish momentum will continue.

Neurogene Inc. (NGN), a clinical-stage biotechnology company, has seen a notable uptick in its stock price, as evidenced by the 15-minute chart displaying a significant bullish trend. The KDJ Golden Cross and Bullish Marubozu at 09/09/2025 12:15 indicate a shift in momentum towards the upside, suggesting potential for further price increases. This trend is supported by buyers maintaining control of the market, which suggests that the bullish momentum is likely to continue.

Neurogene is developing genetic medicines for rare neurological diseases with high unmet needs. Its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is at the core of its product portfolio. NGN-401, a product under development for the treatment of Rett syndrome, is currently in a Phase 1/2 open-label, multi-center clinical trial. NGN-101, another product in development, is intended for the treatment of CLN5 Batten disease Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4)^[1].

The stock's recent performance reflects investor optimism about Neurogene's pipeline and the potential of its EXACT platform to address unmet medical needs. As the company continues to advance its clinical trials and develop new treatments, investors should closely monitor its progress to gauge the potential for further stock appreciation.

References:
Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4)^[1] https://www.marketscreener.com/news/neurogene-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ce7d59d9df8bfe24